Jane Street’s Taysha Gene Therapies TSHA Stock Holding History

Jane Street’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$260K	Sell	38,200 -75,400	-66%	-$446K	﹤0.01%	9517
2026 Q1	$508K	Buy	113,600 +28,800	+34%	+$134K	﹤0.01%	7996
2025 Q4	$466K	Buy	84,800 +71,400	+533%	+$347K	﹤0.01%	7856
2025 Q3	$43.8K	Sell	13,400 -200	-1%	-$566	﹤0.01%	10385
2025 Q2	$31.4K	Buy	+13,600	New	+$29.5K	﹤0.01%	9280
2024 Q1	–	Sell	-11,600	Closed	-$20.5K	–	10094
2023 Q4	$20.5K	Sell	11,600 -24,700	-68%	-$49.2K	﹤0.01%	8906
2023 Q3	$115K	Buy	+36,300	New	+$67.8K	﹤0.01%	7898

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street's TSHA Position: Q2 2026 in Review

Jane Street opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 228,355 shares worth $1.56M. The stake represents ﹤0.01% of the portfolio and ranks #5622 among its holdings. This is a return to the name: Jane Street previously reported a position in TSHA as recently as Q4 2025.

Jane Street first reported a position in TSHA in Q3 2020 and has held it in 10 quarters since. The position peaked at $1.82M in Q3 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Jane Street held 228,355 shares of Taysha Gene Therapies worth $1.56M as of Q2 2026.
Taysha Gene Therapies was a new Jane Street position in Q2 2026.
Taysha Gene Therapies made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #5622 holding.
Jane Street first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 10 quarters since.
Jane Street's Taysha Gene Therapies position peaked at $1.82M in Q3 2025.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.